Cross-sex hormone use does not increase cardiovascular risk in young male-to-female transsexuals: a study of self-medication by healthy Thai cabaret dancers
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Hembree WC, Cohen-Kettenis P, Henriette A, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ 3rd, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009; 94:3132-54.10.1210/jc.2009-034519509099HembreeWCCohen-KettenisPHenrietteADelemarre-vande Waal HAGoorenLJMeyerWJ3rdet alEndocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline20099431325419509099Open DOISearch in Google Scholar
Meyer W 3rd, Bockting WO, Cohen-Kettenis P, Coleman E, Diceglie D, Devor H, et al. The Harry Benjamin gender dysphoria association’s standard of care for gender identities disorders, sixth version. J Psychol Human Sexuality. 2002; 13:1-30.10.1300/J056v13n01_01MeyerW3rdBocktingWOCohen-KettenisPColemanEDiceglieDDevorHet alThe Harry Benjamin gender dysphoria association’s standard of care for gender identities disorders, sixth version200213130Open DOISearch in Google Scholar
Baltgalvis KA, Greising SM, Warren GL, Lowe DA. Estrogen regulates estrogen receptors and antioxidant gene expression in mouse skeletal muscle. PLoS One. 2010; 13:e10164.BaltgalvisKAGreisingSMWarrenGLLoweDAEstrogen regulates estrogen receptors and antioxidant gene expression in mouse skeletal muscle201013e1016410.1371/journal.pone.0010164285414020405008Search in Google Scholar
Bardra KD, Leslie G F. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. Eur J Cancer Prevention. 2007; 16:232-4.10.1097/CEJ.0b013e328011ed2dBardraKDLeslieG FHormonal interventions to prevent hormonal cancers: breast and prostate cancers200716232417415094Open DOISearch in Google Scholar
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288:321-33.1211739710.1001/jama.288.3.321RossouwJEAndersonGLPrenticeRLLaCroixAZKooperbergCStefanickMLet alRisks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial20022883213312117397Search in Google Scholar
Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et at. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HER II). JAMA. 2002; 288:58-64.10.1001/jama.288.1.58HulleySFurbergCBarrett-ConnorECauleyJGradyDHaskellWetatNoncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HER II)2002288586412090863Open DOISearch in Google Scholar
Miller VT, Larosa J, Barnabei V, Kessler C, Levin G, Smith-Roth A, et al. Effect of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. JAMA. 1995; 273:199-208.10.1001/jama.1995.035202700330287807658MillerVTLarosaJBarnabeiVKesslerCLevinGSmith-RothAet alEffect of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial1995273199208Open DOISearch in Google Scholar
Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr. 2000; 7: 39-66.BoslandMCThe role of steroid hormones in prostate carcinogenesis20007396610.1093/oxfordjournals.jncimonographs.a02424410963619Search in Google Scholar
Herrmann BL, Saller B, Janssen OE, Gocke P, Bockisch A, Sperling H, et al. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endrocinol Metab. 2002; 87: 5476-8.10.1210/jc.2002-020498HerrmannBLSallerBJanssenOEGockePBockischASperlingHet alImpact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene2002875476812466340Open DOISearch in Google Scholar
Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010; 72:1-10.1947317410.1111/j.1365-2265.2009.03632.xElaminMBGarciaMZMuradMHErwinPJMontoriVMEffect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses20107211019473174Search in Google Scholar
Asscheman H, Gooren LJ, Eklund PL. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism. 1989; 38:869-73.252805110.1016/0026-0495(89)90233-3AsschemanHGoorenLJEklundPLMortality and morbidity in transsexual patients with cross-gender hormone treatment19893886973Search in Google Scholar
Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, et al. Long-term evaluation of CSH treatment in transsexual persons. J Sex Med. 2012; 9:2641-51.10.1111/j.1743-6109.2012.02876.xWierckxKMuellerSWeyersSVanCaenegem ERoefGHeylensGet alLong-term evaluation of CSH treatment in transsexual persons20129264151Open DOISearch in Google Scholar
Vasan RS. Biomarker of cardiovascular disease: molecular basis and practical consideration. Circulation. 2006; 113:2335-62.10.1161/CIRCULATIONAHA.104.482570VasanRSBiomarker of cardiovascular disease: molecular basis and practical consideration2006113233562Open DOISearch in Google Scholar
Emerging Risks Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012; 367:1310-20.2303402010.1056/NEJMoa1107477EmergingRisks Factors CollaborationKaptogeSDiAngelantonio EPennellsLWoodAMWhiteIRet alC-reactive protein, fibrinogen, and cardiovascular disease prediction2012367131020Search in Google Scholar
Lindermalm G, Korlin D, Uddenberg N. Long-term follow-up of “sex change” in 13 male-to-female transsexuals. Arch Sex Behav. 1986; 15:187-210.10.1007/BF015424123729700LindermalmGKorlinDUddenbergNLong-term follow-up of “sex change” in 13 male-to-female transsexuals198615187210Open DOISearch in Google Scholar
Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with CSH: extensive personal experience. J Clin Endocrinol Metab. 2008; 93:19-25.10.1210/jc.2007-1809GoorenLJGiltayEJBunckMCLong-term treatment of transsexuals with CSH: extensive personal experience2008931925Open DOISearch in Google Scholar
Winter S. Thai transgenders in focus: demographics, transitions and identities. Int J Transgender. 2006; 9: 15-27.10.1300/J485v09n01_03WinterSThai transgenders in focus: demographics, transitions and identities200691527Open DOISearch in Google Scholar
Chokrungvaranont P, Selvaggi G, Jindarak S, Angspatt A, Pungrasmi P, Suwajo P, et al. The development of sex assignment surgery in Thailand: a social perspective. Sci. World J. 2014;19:182981.ChokrungvaranontPSelvaggiGJindarakSAngspattAPungrasmiPSuwajoPet alThe development of sex assignment surgery in Thailand: a social perspective201419182981Search in Google Scholar
US Department of Health and Human Service. JNC 7 Express. The seventh report of the joint national committee in prevention, detection, evaluation, and treatment of high blood pressure. National Institute of Health. 2003.US Department of Health and Human Service. JNC 7 Express. The seventh report of the joint national committee in prevention, detection, evaluation, and treatment of high blood pressure2003Search in Google Scholar
Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011; 164:635-42.2126654910.1530/EJE-10-1038AsschemanHGiltayEJMegensJAdeRonde WPvanTrotsenburg MAGoorenLJA long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones201116463542Search in Google Scholar
Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer. 1998; 83:1561-6.10.1002/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-ZDiamondTCampbellJBryantCLynchWThe effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma19988315616Open DOISearch in Google Scholar
Herrmann BL, Saller B, Janssen OE. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 Gene. J. Clin Endocrinol Metab. 2002; 87: 5476-84.10.1210/jc.2002-020498HerrmannBLSallerBJanssenOEImpact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 Gene200287547684Open DOISearch in Google Scholar
Ott J, Aust S, Promberger R, Huber JC, Kaufmann U. Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals. J Sex Med. 2011; 8:2361-9.2159583410.1111/j.1743-6109.2011.02311.xOttJAustSPrombergerRHuberJCKaufmannUCross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals2011823619Search in Google Scholar
Venkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, et al. Effects of oral transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins postmenopausal women. Thromb Haemost. 2001; 85:619-25.11341495VenkavaaraSSilveiraAHakala-Ala-PietilaTVirkamakiAHovattaOHamstenAet alEffects of oral transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins postmenopausal women2001856192510.1055/s-0037-1615643Search in Google Scholar
Prestwood KM, Unson C, Kulldorff M, Cushman M. The effect of different doses of micronized 17b-estradiol on C-reactive protein, interleukin-6, and lipids in older women. J Gerontol A Biol Sci Med Sci. 2004; 59:827-32.10.1093/gerona/59.8.M827PrestwoodKMUnsonCKulldorffMCushmanMThe effect of different doses of micronized 17b-estradiol on C-reactive protein, interleukin-6, and lipids in older women20045982732Open DOISearch in Google Scholar
Giltay EJ, Gooren LJ, Emeis JJ, Kooistra T, Stehouwer CD. Oral ethinyl estradiol, but not transdermal 17-estradiol, increases plasma C-reactive protein levels in men. Thromb Haemost. 2000; 84:359-60.GiltayEJGoorenLJEmeisJJKooistraTStehouwerCDOral ethinyl estradiol, but not transdermal 17-estradiol, increases plasma C-reactive protein levels in men2000843596010.1055/s-0037-1614026Search in Google Scholar
New G, Timmins KL, Duffy SJ, Tran BT, O’Brien RC, Harper RW, Meredith IT. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol. 1997; 29:1437-44.10.1016/S0735-1097(97)00080-69180101NewGTimminsKLDuffySJTranBTO’BrienRCHarperRWMeredithITLong-term estrogen therapy improves vascular function in male to female transsexuals199729143744Open DOISearch in Google Scholar
Lerer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 2005; 95:961-2.10.1111/j.1464-410X.2005.05447.x15839913LererSDiamondEJMamkineBDrollerMJStoneNNStockRGC-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer200595961215839913Open DOISearch in Google Scholar
van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997; 47:337-42.10.1046/j.1365-2265.1997.2601068.x9373456vanKesteren PJAsschemanHMegensJAGoorenLJMortality and morbidity in transsexual subjects treated with cross-sex hormones199747337429373456Open DOISearch in Google Scholar
Martinez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care. 2007; 12:97-106.1755900610.1080/13625180701300194MartinezFAvecillaACombined hormonal contraception and venous thromboembolism2007129710617559006Search in Google Scholar